30 FEATURE
Society Pages :
NOW AVAILABLE ...
The ASH Clinical News iPad App !
The latest news and views for the broader hematology / oncology community , now delivered to your iPad .
Editor ’ s Corner Alice Ma ’ s Hematology Wishlist
ASH Directions Announcing the 2017 Scholar Award Recipients
Written in Blood Cytomegalovirus Infection and the Risk of Acute Lymphocytic Leukemia
Literature Scan Can Overly Restrictive Exclusion Criteria Block Patients from Effective Therapy ?
DEPARTMENTS
CONTENTS
7 UP FRONT 11 CLINICAL NEWS 29 TRAINING AND EDUCATION
On Location : Highlights from the ASH Annual Meeting
Your source for worldwide news and perspectives on hematology / oncology
volume 03 | number 01
PREDATORY JOURNALS on the PROWL january 2017
Download the free app from the iTunes App Store
33 BACK OF THE BOOK
www . ASHClinicalNews . org
In a publish-or-perish environment , authors are becoming the prey
Recent Promotions and Transitions
Latest & Greatest : Drug and Device News
You Make the Call : Anticoagulation and Pregnancy
VONVENDI [ von Willebrand factor ( Recombinant )] Brief Summary of Prescribing Information . Please see package insert for full Prescribing Information
INDICATIONS AND USAGE
VONVENDI [ von Willebrand factor ( Recombinant )] is a recombinant von Willebrand factor indicated for on-demand treatment and control of bleeding episodes in adults ( age 18 and older ) diagnosed with von Willebrand disease .
CONTRAINDICATIONS
VONVENDI is contraindicated in patients who have had lifethreatening hypersensitivity reactions to VONVENDI or constituents of the product ( tri-sodium citrate-dihydrate , glycine , mannitol , trehalosedihydrate , polysorbate 80 , and hamster or mouse proteins ).
WARNINGS AND PRECAUTIONS
Embolism and Thrombosis Thromboembolic reactions , including disseminated intravascular coagulation ( DIC ), venous thrombosis , pulmonary embolism , myocardial infarction , and stroke , can occur , particularly in patients with known risk factors for thrombosis . Monitor for early signs and symptoms of thrombosis such as pain , swelling , discoloration , dyspnea , cough , hemoptysis , and syncope .
In patients requiring frequent doses of VONVENDI with recombinant factor VIII , monitor plasma levels for FVIII : C activity because an excessive rise in factor VIII levels can increase the risk of thromboembolic complications .
Hypersensitivity Reactions Hypersensitivity reactions , including anaphylaxis , may occur . Symptoms can include anaphylactic shock , generalized urticaria , angioedema , chest tightness , hypotension , shock , lethargy , nausea , vomiting , paresthesia , pruritus , restlessness , wheezing and / or acute respiratory distress . If signs and symptoms of severe allergic reactions occur , immediately discontinue administration of VONVENDI and provide appropriate supportive care .
VONVENDI contains trace amounts of mouse immunoglobulin G ( MuIgG ) and hamster proteins less than or equal to 2 ng / IU VONVENDI . Patients treated with this product may develop hypersensitivity reactions to non-human mammalian proteins .
Neutralizing Antibodies Neutralizing antibodies ( inhibitors ) to von Willebrand factor and / or factor VIII can occur . If the expected plasma levels of VWF activity ( VWF : RCo ) are not attained , perform an appropriate assay to determine if anti-VWF or anti-FVIII inhibitors are present . Consider other therapeutic options and direct the patient to a physician with experience in the care of either von Willebrand disease or hemophilia A .
In patients with high levels of inhibitors to VWF or factor VIII , VONVENDI therapy may not be effective and infusion of this protein may lead to severe hypersensitivity reactions . Since inhibitor antibodies can occur concomitantly with anaphylactic reactions , evaluate patients experiencing an anaphylactic reaction for the presence of inhibitors .
Monitoring Laboratory Tests
• Monitor plasma levels of VWF : RCo and factor VIII activities in patients receiving VONVENDI to avoid sustained excessive von Willebrand factor and / or factor VIII activity levels , which may increase the risk of thrombotic events , particularly in patients with known clinical or laboratory risk factors .
• Monitor for development of von Willebrand factor and / or factor VIII inhibitors when suspected . Perform appropriate inhibitor assays to determine if von Willebrand factor and / or factor VIII inhibitors are present if bleeding is not controlled with the expected dose of VONVENDI .
ADVERSE REACTIONS
The most common adverse reaction observed in ≥2 % of subjects in clinical trials ( n = 66 ) was generalized pruritus .
Clinical Trials Experience Because clinical trials are conducted under widely varying conditions , adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice .
The safety profile of VONVENDI was evaluated in three prospective , multicenter trials ; two were conducted in subjects with von Willebrand disease ( n = 66 ) and one was conducted in subjects with hemophilia A ( n = 12 ). The adverse reactions reported in the two von Willebrand disease trials are listed in Table 1 .
Table 1 : Summary of Adverse Reactions in Patients with von Willebrand Disease a
System Organ Class ( SOC )
Adverse Reaction a
This trial was done using ADVATE [ Antihemophilic factor ( Recombinant )], a recombinant factor VIII .
Immunogenicity The immunogenicity of VONVENDI was assessed in clinical trials by assessing the development of neutralizing antibodies against rVWF and rFVIII , as well as binding antibodies against rVWF , rFurin , Chinese hamster ovary ( CHO ) protein and mouse IgG . No treatment-related development of binding or neutralizing antibodies against VWF or of neutralizing antibodies against FVIII was observed . Moreover , binding antibodies against potential impurities such as rFurin , CHO-protein or mouse IgG did not develop after treatment with VONVENDI .
The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay . Additionally , the observed incidence of antibody ( including neutralizing antibody ) positivity in an assay may be influenced by several factors including assay methodology , sample handling , timing of sample collection , concomitant medications , and underlying disease . For these reasons , it may be misleading to compare the incidence of antibodies to VONVENDI in the studies described above with the incidence of antibodies in other studies or to other products .
© 2016 Shire US Inc ., Lexington , MA 02421 . All rights reserved . 1-800-828-2088 .
BAXALTA and VONVENDI are trademarks or registered trademarks of Baxalta Incorporated , a wholly owned , indirect subsidiary of Shire plc . SHIRE and the Shire Logo are trademarks or registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates . Patented : see www . shire . com / productpatents /.
Baxalta US Inc . Westlake Village , CA 91362 USA U . S . License No . 2020 Printed in USA Issued : 12 / 2015
S24720 11 / 16
Number of Subjects (%) ( n = 66 )
Number of Infusions (%) ( n = 355 )
Cardiac Disorders Tachycardia 1 ( 1.52 %) 1 ( 0.28 %)
Gastrointestinal Disorders
General Disorders and Administration Site Conditions
Skin and Subcutaneous Tissues Disorders
Vascular Disorder
Nervous System Disorders
Nausea 1 ( 1.52 %) 1 ( 0.28 %)
Infusion site paresthesia
1 ( 1.52 %) 1 ( 0.28 %)
Chest discomfort 1 ( 1.52 %) 1 ( 0.28 %)
Generalized pruritus
2 ( 3.03 %) 2 ( 0.56 %)
Hot flush 1 ( 1.52 %) 1 ( 0.28 %) Hypertension 1 ( 1.52 %) 2 ( 0.56 %) Dizziness 1 ( 1.52 %) 1 ( 0.28 %) Dysgeusia 1 ( 1.52 %) 1 ( 0.28 %) Tremor 1 ( 1.52 %) 1 ( 0.28 %)
Investigations Heart rate increase 1 ( 1.52 %) 1 ( 0.28 %)
Electrocardiogram T wave inversions 1 ( 1.52 %) 1 ( 0.28 %)